The Highest Ever Reported Level of Carbohydrate Antigen 19-9: A Case Report | Al-Khallaf | Journal of Medical Cases
Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colon Cancer
SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Common benign HPB conditions with associated deranged CA19.9 level | Download Table
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - HPB
References in How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Clinical analysis of four serum tumor markers in 458 patients with ova | CMAR
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text
Tumor Marker:- Part 7 - CA 125 and CA 19-9 - Labpedia.net
CA19-9 for detecting recurrence of pancreatic cancer | Scientific Reports
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
Tumor Marker Control | Fujirebio
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
Tumor Biomarkers For Screening, Progression and Prognosis
CA 19-9 as a serum marker in urothelial carcinoma Pall M, Iqbal J, Singh SK, Rana SV - Urol Ann
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png "PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar")